45
Participants
Start Date
November 16, 2021
Primary Completion Date
September 1, 2024
Study Completion Date
September 1, 2025
FMT + ICI
"This study will include 3 cohorts of patients: (1) Patients with advanced or unresectable NSCLC, (2) patients with advanced or unresectable melanoma, and (3) patients with unresectable or advanced uveal melanoma. Patients with NSCLC, melanoma, uveal melanoma and will be analyzed in three separate subgroups given their differing clinical outcomes.~Each group will be treated with ICI as per their respective first line options, in combination with investigational FMT capsules."
London Health Sciences Centre, London
DRCC Lakeridge Health, Oshawa
Sunnybrook Health Sciences Centre/Sunnybrook Research Institute, Toronto
Centre hospitalier de l'Université de Montréal (CHUM), Montreal
McGill University Health Center, Montreal
CHU de Québec, Centre intégré en cancérologie (CIC), Hôpital de L'Enfant-Jésus, Québec
Centre hospitalier de l'Université de Montréal (CHUM)
OTHER